All Clinical Trials
Note: The LRG uses ClinicalTrials.gov and other sources to compile the LRG Clinical Trials database. Click on the name (title) to see the trial details in the LRG database. Click on the NCT link (below) to see the trial details in ClinicalTrials.gov.
332 trials found
Drug |
NCT# |
||
|---|---|---|---|
| Symptom Inventory for Gastrointestinal Stromal Tumors | |||
| Apatinib Mesylate | Apatinib Mesylate (Rivoceranib) Versus Standard Second-line TKI in the Treatment of Advanced GIST | ||
| Avapritinib | Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST | ||
| Avapritinib | Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA | ||
| ddPCR | Cross-Platform Biomarker Program for Establishment and Validation of Liquid Biopsy for Clinical Decision Making in resectable gastrointestinal stromal tumour (GIST) | ||
| Imatinib | Effect of Imatinib on Bone Metabolism in Patients With Chronic Myelogenous Leukemia or Gastrointestinal Stromal Tumors | ||
| Imatinib | A Retrospective Pharmacokinetics and Pharmacogenomics Research of Imatinib in Gastrointestinal Stromal Tumor Treatment | ||
| Imatinib + Sunitinib + Regorafenib | GIST: Assessment of Tumor Mutations and TKI Plasma Exposure | ||
| Imatinib, Nilotinib | A Global Imatinib and Nilotinib Pregnancy Exposure Registry | ||
| Nilotinib | Nilotinib Pharmacokinetics (PK) in Gastrointestinal Stromal Tumor (GIST) | ||
| None | Gastrointestinal Stromal Tumors (GIST) Registry | ||
| None | Kinase Genotyping of Gastro Intestinal Stomach Tumors (GISTs) From Patients Enrolled in Pfizer A6181112 Phase IIIb Trial | ||
| Regorafenib (BAY 73-4506) | Regorafenib in Subjects With Gastrointestinal Stromal Tumors (GIST) Who Have Progressed After Standard Therapy (Managed Access Program) | ||
| Ripretinib | Ripretinib Used for Resectable Metastatic GIST After Failure of Imatinib Therapy | ||
| Sunitinib or Sorafenib | Study on the Influence of Sunitinib and Sorafenib on Fatigue, Quality of Life and Depression in Patients With Metastatic Renal Cell Cancer or Gastrointestinal Stromal Tumor (GIST) | ||
| Surgery | Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis | ||
| MAAT | Cognitive Impairment in GIST Patients on Tyrosine Kinase Inhibitor Therapy: Cognitive Behavioral Therapy to Improve Cognitive Symptoms (GIST-MAAT) | 0 |
|
| Surgery | Liver Transplantation for Unresectable GIST Liver Metastases (TRANSGIST) | 0 |
|
| ARQ 092 | Phase 1 Dose Escalation Study of ARQ 092 in Adult Subjects With Advanced Solid Tumors and Recurrent Malignant Lymphoma | 1 |
|
| AT13387 | Study to Assess the Safety of Escalating Doses of AT13387 in Patients With Metastatic Solid Tumors | 1 |
|
| AUY922 | Phase I-II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 in Advanced Solid Malignancies, and Efficacy in HER2+ or ER+ Locally Advanced or Metastatic Breast Cancer Patients. | 1 |
|
| BAY80-6946 + BAY86-9766 | Phase Ib Study of PI3(Phosphoinositol 3)-Kinase Inhibitor BAY80-6946 With MEK (Mitogen-activated Protein Kinase) Inhibitor BAY86-9766 in Patients With Advanced Cancer | 1 |
|
| BBI503 | A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors | 1 |
|
| BEZ235 | A Phase I/II Study of BEZ235 in Patients With Advanced Solid Malignancies Enriched by Patients With Advanced Breast Cancer | 1 |
|
| BEZ235 + MEK162 | Safety, Pharmacokinetics and Pharmacodynamics of BEZ235 Plus MEK162 in Selected Advanced Solid Tumor Patients | 1 |
|
| BGT226 | A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast Cancer | 1 |
|
| BIIB021 (CNF2024) | Study of Oral CNF2024 in Advanced Solid Tumors | 1 |
|
| BIIB021 (CNF2024) | Once or Twice Daily Administration of BIIB021 to Subjects With Advanced Solid Tumors | 1 |
|
| BIIB022 | Phase 1 Study of BIIB022 (Anti-IGF-1R Monoclonal Antibody) in Relapsed/Refractory Solid Tumors | 1 |
|
| BIIB028 | Administration of BIIB028 to Subjects With Solid Tumors | 1 |
|
| Binimetinib + Pexidartinib | A Study of MEK162 (Binimetinib) in Combination With Pexidartinib in Patients With Advanced Gastrointestinal Stromal Tumor (GIST) | 1 |
|
| BKM120 | A Phase IA, Multi-Center, Open-Label, Dose- Escalation Study of BKM120, Administered Orally on a Continuous Daily Dosing Schedule in Adult Patients with Advanced Solid Malignancies | 1 |
|
| BKM120 + GSK1120212 | A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients | 1 |
|
| BKM120 + MEK162 | Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients | 1 |
|
| BLU-285 | (NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors | 1 |
|
| BMS-754807 | Multiple Dose Study In Cancer Patients: Safety and Tolerability of BMS-754807 in Advanced or Metastatic Solid Tumors | 1 |
|
| BMS-754807 | Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan | 1 |
|
| Bortezomib + Sunitinib | A Phase I Trial of Bortezomib and Sunitinib | 1 |